Recently, it was demonstrated that microtubule-targeted agents (MTAs), including vinorelbine and eribulin, activate the STING pathway leading to type I IFN production in human breast cancer and leukemia monocytic cell lines (12, 28). The gene discussed is STING1; the disease is leukemia.